Early treatment of pediatric-onset relapsing-remitting multiple sclerosis (MS) with high-efficacy therapy (HET) is associated with substantially slower disability progression than treatment with low-efficacy therapies or no […]

The Epstein-Barr virus (EBV) is our constant companion, infecting an estimated 90%-95% of adults. Many of us are first infected as children, when the germ may […]

TOPLINE: Over time, exercising at least twice a week is associated with significantly fewer insomnia symptoms and better sleep duration, new research shows. METHODOLOGY: The study […]

TOPLINE: Earlier treatment with erenumab was associated with significantly better migraine prevention than that with nonspecific oral migraine preventive medications (OMPMs) in patients with resistant episodic […]

TOPLINE: Discontinuing high-efficacy therapies (HETs) that affect immune cell trafficking such as natalizumab and fingolimod is associated with a significant increased relapse risk in older adults […]

TOPLINE: Receipt of the bivalent COVID-19 vaccine was not associated with an increased stroke risk in the first 6 weeks after vaccination with either the Pfizer […]

TOPLINE: Age-standardized stroke rates decreased in the United States between 1990 and 2019, while absolute stroke incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates increased, […]

A simple skin biopsy test is able to detect an abnormal form of alpha-synuclein with high accuracy in individuals with neurodegenerative disorders such as Parkinson’s disease […]

The US Food and Drug Administration (FDA) has expanded the indication for the long-acting C5 complement inhibitor, ravulizumab (Ultomiris, Alexion), to include adults with anti–aquaporin-4 (AQP4) […]